Nadroparin

Jump to: navigation, search
Nadroparin
Clinical data
ATC code
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar massMean MW = 4500 Daltons

WikiDoc Resources for Nadroparin

Articles

Most recent articles on Nadroparin

Most cited articles on Nadroparin

Review articles on Nadroparin

Articles on Nadroparin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nadroparin

Images of Nadroparin

Photos of Nadroparin

Podcasts & MP3s on Nadroparin

Videos on Nadroparin

Evidence Based Medicine

Cochrane Collaboration on Nadroparin

Bandolier on Nadroparin

TRIP on Nadroparin

Clinical Trials

Ongoing Trials on Nadroparin at Clinical Trials.gov

Trial results on Nadroparin

Clinical Trials on Nadroparin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nadroparin

NICE Guidance on Nadroparin

NHS PRODIGY Guidance

FDA on Nadroparin

CDC on Nadroparin

Books

Books on Nadroparin

News

Nadroparin in the news

Be alerted to news on Nadroparin

News trends on Nadroparin

Commentary

Blogs on Nadroparin

Definitions

Definitions of Nadroparin

Patient Resources / Community

Patient resources on Nadroparin

Discussion groups on Nadroparin

Patient Handouts on Nadroparin

Directions to Hospitals Treating Nadroparin

Risk calculators and risk factors for Nadroparin

Healthcare Provider Resources

Symptoms of Nadroparin

Causes & Risk Factors for Nadroparin

Diagnostic studies for Nadroparin

Treatment of Nadroparin

Continuing Medical Education (CME)

CME Programs on Nadroparin

International

Nadroparin en Espanol

Nadroparin en Francais

Business

Nadroparin in the Marketplace

Patents on Nadroparin

Experimental / Informatics

List of terms related to Nadroparin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nadroparin is a form of low molecular weight heparin.

External Links

  • http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
  • http://www.mayoclinic.com/health/drug-information/DR600971
  • Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417.

References


Linked-in.jpg